Back to search results

Automated Image-Guided DBS for Parkinson's Disease

This study is testing a new automated deep brain stimulation (DBS) algorithm called Illumina 3D, developed by Boston Scientific, for people with Parkinson's disease (PD). The goal is to see if this automated system can effectively improve motor symptoms. You might be able to join if you have PD and are newly implanted or soon to be implanted with a Boston Scientific DBS device. The study will compare how well your motor symptoms improve when your DBS is programmed using the standard method versus the new Illumina 3D algorithm. Success will be measured by changes in your QDG Mobility Score. About 15 people are expected to participate.

Study design
This interventional study plans to enroll 15 participants. It compares different settings of a Boston Scientific DBS device, including a standard setting and several settings determined by the Illumina 3D algorithm.
What's involved
You will have your DBS device turned off for 45 minutes, and then turned on with different settings for 45 minutes each. You will also need to be willing to temporarily stop your Parkinson's medication for research visits.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at Baseline and after 45 minutes of Illumina 3D DBS, suggesting a short follow-up period for this specific measurement.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07215481

Automated Image-Guided Programming of Deep Brain Stimulation (DBS) for Parkinson's Disease

Not Yet Recruiting
NAAges 21+InterventionalTreatment
Stanford University
~15 participants
Updated 2026-04-27 on ClinicalTrials.gov
What's tested:Shame Control (Baseline)Standard of Care Deep Brain StimulationIllumina 3D Deep Brain StimulationIllumina 3D Deep Brain Stimulation Reduced AmplitudeIllumina 3D Deep Brain Stimulation Higher Amplitude

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in QDG Mobility Score (OFF DBS to Illumina 3D)
Measured over Baseline and after 45 minutes of Illumina 3D DBS

Conditions

Parkinson's Disease (PD)

Explore related trials

Parkinson Disease

NCT07215481

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Stanford Neuroscience Health Clinic

    Stanford, Californiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Helen Bronte-Stewart, MD, MSE · PRINCIPAL_INVESTIGATOR · Stanford University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of Parkinson's disease (PD)
Newly implanted or soon to be implanted with deep brain stimulation (Boston Scientific device)
Willingness to withdraw from clinical medication regimen when necessary for research visits

Exclusion

Dementia
Unable or unwilling to come OFF DBS for a short period of time

What this trial measures

  • Change in QDG Mobility Score (OFF DBS to Illumina 3D)Baseline and after 45 minutes of Illumina 3D DBS

    Quantitative Digitography (QDG) Mobility Score is a single score representing a participant's overall movement proficiency by combining performance across different aspects of movement including speed, frequency, amplitude, and rhythmicity measured using an engineered Keyduo QDG device during an alternating finger pressing and releasing with the index and middle finger. It is represented by a single value between 0 and 100 for each hand, where 100 represents ideal performance. The primary outcome is the difference in QDG Mobility Score from the OFF DBS condition (baseline) to Illumina 3D DBS. The Illumina 3D DBS amplitude condition with the highest QDG mobility score will be used.